Jefferies Sees Reduced Visibility for Replimune Group, Inc. (REPL) Following FDA Decision
TheFly reported on April 13 that Jefferies cut its rating on REPL from Buy to Hold and reduced its price target sharply to $2 from $13.
Replimune Group Inc. (REPL)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 11,045,336 | $84,496,820 | 0.49% | |
| 2. | Suvretta Capital Management Aaron Cowen | 4,221,836 | $32,297,045 | +11615% | 0.82% |
| 3. | D E Shaw D. E. Shaw | 2,336,528 | $17,874,440 | -10% | 0.01% |
| 4. | ADAR1 Capital Management Daniel Schneeberger | 1,582,987 | $12,109,851 | +28% | 0.71% |
| 5. | Boxer Capital Aaron Davis And Christopher Fuglesang | 1,175,000 | $8,988,750 | +57% | 1.18% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.61 | 1,100,000 | $14,971,000.00 | 1,100,000 | 2019-11-18 | Filing | |
| $13.61 | 220,000 | $2,994,200.00 | 5,328,939 | 2019-11-18 | Filing | |
| $15.00 | 133,333 | $1,999,995.00 | 4,721,449 | 2018-07-24 | Filing | |
| $15.00 | 6,667 | $100,005.00 | 6,667 | 2018-07-24 | Filing | |
| $15.00 | 133,333 | $1,999,995.00 | 4,721,449 | 2018-07-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.24 | 12,000 | $110,880.00 | 180,962 | 2026-06-01 | Filing | |
| $5.08 | 14,023 | $71,236.84 | 235,662 | 2026-05-18 | Filing | |
| $5.08 | 7,894 | $40,101.52 | 107,057 | 2026-05-18 | Filing | |
| $5.08 | 8,626 | $43,820.08 | 192,962 | 2026-05-18 | Filing | |
| $5.08 | 17,657 | $89,697.56 | 1,412,414 | 2026-05-18 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 7,356,916 | $56,280,407 | 0.56% | |
| 2. | 6,239,239 | $47,730,179 | 0% | |
| 3. | 3,782,237 | $28,934,113 | 0% | |
| 4. | 2,808,368 | $21,484,015 | 2.97% | |
| 5. | 2,759,120 | $21,107,268 | 0% |
News See All
10 Best Biotech Stocks Under $10 to Buy
According to Eli Casdin, CEO of Casdin Capital, biotech is currently experiencing a momentary stop despite being in one of the best economic environments in years.
Replimune Group (REPL) Nosedives 39% as FDA Approval for Melanoma Treatment 'Uncertain'
Replimune extended losses to a second consecutive day on Thursday, slashing 39.40 percent to close at $3.46 apiece after failing to clear regulatory challenges for its treatment candidate for melanoma...
Replimune Group, Inc. (NASDAQ:REPL) Q4 2025 Earnings Call Transcript
Operator: Good morning and welcome to the Replimune Fiscal Year Fourth Quarter 2025 Financial Results and Corporate Update Conference Call. Currently, all participants are in listen-only mode.
12 Best Medical Stocks to Buy Under $10
In this article, we will take a look at the 12 best medical stocks to buy under $10.
15 Small-Cap Stocks with High Potential
In this article, we will take a look at the 15 small-cap stocks with high potential.
12 Stocks with Biggest Upside Potential According to Analysts
In this article, we will take a look at the 12 stocks with biggest upside potential according to analysts.
5 Best Stocks to Buy Under $20 According to Jeremy Green's Redmile Group
In this piece, we will take a look at the top five best stocks to buy under $20 according to Jeremy Green's Redmile Group.
Is REPL A Good Stock To Buy Now?
In this article we will take a look at whether hedge funds think Replimune Group, Inc. (NASDAQ:REPL) is a good investment right now.
Replimune Group, Inc. (REPL): Hedge Funds Are Reducing Exposure
We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March...